Gilead Sciences Inc $91.55

down -2.24


31/7/2014 04:00 PM  |  NASDAQ : GILD  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get GILD Trend Analysis - it has outperformed the S&P 500 by 35%

Partner Headlines

  1. Merck, J&J, Baxter Provide Healthy Dividend Stream

    IBD
  2. Aetna Earnings Beat But Rising Medical Costs A Worry

    IBD
  3. #PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On ...

    Benzinga
  4. Creating Cures And Dividends Where None Existed Before With Gilead Sciences

    GuruFocus
  5. Q2 Revenue Best Since 2012

    IBD
  6. Q2 Revenue Strongest Since 2012 As Recovery Quickens

    IBD
  7. AbbVie Beats Earnings Views, Sees Slower Humira Gain

    IBD
  8. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  9. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  10. Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug

    Benzinga
  11. Biogen, Gilead Profits Soar

    IBD
  12. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  13. Markets Mostly Higher As Earnings Season Continues To Impress

    Benzinga
  14. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  15. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  16. Statement from FDA Confirms Approval of Gilead's Zydelig

    Benzinga
  17. Earnings Scheduled For July 23, 2014

    Benzinga
  18. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  19. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  20. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  21. Investors Focus On Earnings Rather Than Geopolitical Tensions

    Benzinga
  22. Biotech Enters Reporting Season With Large Caps Central To Sector Performance

    Benzinga
  23. Stocks Up In Late Trade; AerCap Nears Resistance

    IBD
  24. Stocks Add To Gains; Under Armour Rebounds

    IBD
  25. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  26. J&J Earnings Beat Estimates, But Guidance Mixed

    IBD
  27. Economic News Today: Yellen Says Some Stock Valuations 'Stretched'

    IBD
  28. Biogen's Profit Rolls Amid Recent Drug Launches

    IBD
  29. Senate grills Gilead on price

    IBD
  30. Stocks Mixed In Low-Volume Session; Facebook Firms Up

    IBD
  31. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  32. Stocks Hitting 52-Week Highs

    Benzinga
  33. J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views

    Benzinga
  34. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  35. Japan approves BMY regimen

    IBD
  36. Warmer Weather Improving Q2 Earnings Forecasts

    IBD
  37. Biotech Stocks Gilead, Anika Still Near Buy Points

    IBD
  38. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  39. Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics ...

    GuruFocus
  40. IBD 50: Salix, Gilead Among Top Expected EPS Gainers

    IBD
  41. Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week

    IBD
  42. IBD 50: New Drug Driving Gilead's Sales, Earnings

    IBD
  43. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  44. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  45. Stocks Nearly Flat In Quiet Trading With 1 Hour To Go

    IBD
  46. Stocks Edge Higher In Soft Trade; Ambarella Adds To Gains

    IBD
  47. Stocks Up Slightly In Choppy Trade; BitAuto Rallies

    IBD
  48. UPDATE: Morgan Stanley Reiterates On Gilead Sciences On EM Sovaldi

    Benzinga
  49. Stocks Finish Higher; GoPro Extends IPO Advance

    IBD
  50. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
Trading Center